// App-Quantinova.ai

CTIM-17 : EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)

Researchers

Presenter

  • David A Reardon

Principal Investigators

  • Maria Vieito

  • Ghazaleh Tabatabai

  • Agostina Stradella

  • Francois Ghiringhelli

  • Michael C Burger

  • Iris Mildenberger

  • Macarena Gonzalez

  • Alice Hervieu

  • Marta Gil Martin

  • Mirjam Renovanz

  • Mehdi Touat

  • Patrick Y Wen

  • Antje Wick

  • Cecile Gouttefangeas

  • Ana Maia

  • Christophe Bonny

  • Jan Fagerberg

  • Wolfgang Wick

Medical Centers

  • Dana-Farber Cancer Institute, BOSTON, MA, USA

  • Sorbonne Université, AP-HP, ICM, Hôpital Universitaire La Pitié-Salpêtrière, Paris, France

  • Department of Neurology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

  • Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Tübingen, Germany

  • Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, Germany

  • Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France

  • Institut Catala d Oncologia, Hospital Duran i Reynals, Barcelona, Spain

  • Department of Immunology, Eberhard-Karls-University, Tübingen, Germany

  • Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany

  • Department of Neurology, University Hospital Heidelberg, and Clinical Cooperation Unit Neuro-Oncology, German Consortium for Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ)., Heidelberg, Germany

  • Center Georges-Francois Leclerc, Dijon, France

  • Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Enterome, Paris, France

  • Hospital Universitari Vall D'Hebron, Barcelona, Spain

Locations

  • United States

  • Germany

  • France

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • Baculoviral IAP repeat-containing protein5

  • Cluster of Differentiation 4

  • Forkhead box M1

  • Cluster of differentiation 8A

  • Human leukocyte antigen A2

Drug/Treatment

  • Bevacizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I/II

Study Id's

  • NCT04116658

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved